Security Snapshot

MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL) Institutional Ownership

CUSIP: 558868105

13F Institutional Holders and Ownership History from Q2 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

384

Shares (Excl. Options)

23,560,988

Price

$582.34

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
MDGL on Nasdaq
Shares outstanding
22,766,960
Price per share
$533.88
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
23,560,988
Total reported value
$13,715,171,776
% of total 13F portfolios
0.01%
Share change
+198,837
Value change
+$154,180,477
Number of holders
384
Price from insider filings
$533.88
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 558868105.
  • 384 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 384 to 142 between Q4 2025 and Q1 2026.
  • Reported value moved from $13,715,171,776 to $664,740,647.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 384 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 558868105?
CUSIP 558868105 identifies MDGL - MADRIGAL PHARMACEUTICALS, INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FRIEDMAN PAUL A 7.8% $982,730,986 1,814,831 Paul A Friedman, M.D. 10 Dec 2025
Taub Rebecca 7.8% $982,730,986 1,814,831 Rebecca Taub, M.D. 10 Dec 2025
PAULSON & CO. INC. 7.5% $877,768,759 1,707,522 PAULSON & CO. INC. 31 Dec 2025
JANUS HENDERSON GROUP PLC 7% -16% $814,704,393 -$132,548,829 1,584,843 -14% JANUS HENDERSON GROUP PLC 31 Dec 2025

As of 31 Dec 2025, 384 institutional investors reported holding 23,560,988 shares of MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL). This represents 103% of the company’s total 22,766,960 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 9.4% 2,141,701 0% 7.3% $1,247,198,160
RTW INVESTMENTS, LP 8.8% 1,993,687 0% 12% $1,161,003,688
VANGUARD GROUP INC 7.9% 1,808,894 -0.17% 0.02% $1,053,391,331
Avoro Capital Advisors LLC 7.9% 1,807,500 -1.4% 10% $1,052,579,550
PAULSON & CO. INC. 7.5% 1,707,522 -10% 30% $994,358,361
BlackRock, Inc. 7.2% 1,644,750 +5.5% 0.02% $957,803,431
JANUS HENDERSON GROUP PLC 7% 1,584,843 -14% 0.41% $918,203,904
STATE STREET CORP 2.6% 583,003 -11% 0.01% $339,505,967
WELLINGTON MANAGEMENT GROUP LLP 2% 461,402 +14% 0.05% $268,692,841
GEODE CAPITAL MANAGEMENT, LLC 2% 451,743 +1.2% 0.02% $263,113,834
FMR LLC 1.9% 439,398 +9.5% 0.01% $255,879,233
BANK OF AMERICA CORP /DE/ 1.8% 416,025 +70% 0.02% $242,267,998
Invesco Ltd. 1.6% 365,314 +22% 0.03% $212,736,955
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.6% 354,220 -14% 0.58% $206,276,475
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 313,659 -11% 0.02% $182,658,000
GOLDMAN SACHS GROUP INC 1.3% 305,847 -21% 0.03% $178,106,943
Polar Capital Holdings Plc 1.2% 270,151 +1.9% 0.72% $157,319,733
ARMISTICE CAPITAL, LLC 1.2% 265,705 +121% 3.8% $154,730,650
Hood River Capital Management LLC 1.1% 247,560 +2% 1.6% $144,164,090
LORD, ABBETT & CO. LLC 1.1% 244,796 +140% 0.44% $142,555,000
ALKEON CAPITAL MANAGEMENT LLC 1.1% 240,000 +100% 0.61% $139,761,600
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 219,099 +2.5% 0.02% $127,590,112
Artisan Partners Limited Partnership 0.87% 198,693 -3.7% 0.18% $115,706,882
NORGES BANK 0.86% 196,393 0.01% $114,367,500
DEUTSCHE BANK AG\ 0.84% 192,109 +414% 0.04% $111,872,756

Institutional Holders of MADRIGAL PHARMACEUTICALS, INC. - Common Stock (MDGL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,270,826 $664,740,647 -$85,503,434 $523.47 142
2025 Q4 23,560,988 $13,715,171,776 +$154,180,477 $582.34 384
2025 Q3 23,389,191 $10,723,496,299 -$21,867,277 $458.66 352
2025 Q2 23,552,943 $7,127,866,991 -$58,976,553 $302.64 303
2025 Q1 23,618,790 $7,815,274,189 +$242,480,129 $331.23 317
2024 Q4 22,954,039 $7,083,805,672 +$127,209,746 $308.57 282
2024 Q3 22,638,348 $4,763,047,302 -$106,585,037 $212.22 252
2024 Q2 22,870,011 $6,408,116,328 +$504,945,812 $280.16 255
2024 Q1 21,107,869 $5,634,735,243 +$377,318,349 $267.04 263
2023 Q4 19,769,303 $4,574,587,850 +$602,581,939 $231.38 225
2023 Q3 17,386,191 $2,539,343,386 +$349,378,221 $146.04 206
2023 Q2 14,848,153 $3,429,412,203 +$220,213,706 $231.00 208
2023 Q1 13,867,567 $3,359,361,973 +$106,522,160 $242.26 221
2022 Q4 13,305,897 $3,862,135,682 +$567,009,121 $290.25 186
2022 Q3 11,751,595 $763,791,382 -$25,263,206 $64.99 133
2022 Q2 12,001,137 $857,568,681 -$17,315,431 $71.58 130
2022 Q1 12,025,725 $1,179,864,073 +$26,264,521 $98.12 132
2021 Q4 11,953,948 $1,012,214,597 +$40,893,478 $84.74 139
2021 Q3 10,962,747 $874,847,601 -$34,316,604 $79.79 126
2021 Q2 11,229,236 $1,093,866,439 -$99,083,348 $97.41 147
2021 Q1 12,210,439 $1,427,893,568 -$10,189,929 $116.97 135
2020 Q4 12,273,522 $1,364,432,852 +$68,881,092 $111.17 132
2020 Q3 11,637,870 $1,381,764,563 +$46,463,709 $118.73 125
2020 Q2 11,257,505 $1,274,820,026 +$4,793,161 $113.25 124
2020 Q1 11,048,035 $737,557,931 +$26,608,051 $66.76 106
2019 Q4 10,473,886 $954,273,764 +$65,909,446 $91.11 119
2019 Q3 9,642,874 $831,383,218 -$23,303 $86.22 108
2019 Q2 9,609,887 $1,007,125,218 +$10,337,419 $104.81 115
2019 Q1 9,458,074 $1,184,436,498 +$61,292,852 $125.26 133
2018 Q4 8,980,955 $1,012,211,915 -$4,919,869 $112.72 130
2018 Q3 8,620,856 $1,846,093,673 +$62,737,488 $214.13 153
2018 Q2 8,122,360 $2,271,715,929 +$574,219,732 $279.69 148
2018 Q1 6,326,097 $738,823,289 +$151,724,184 $116.79 98
2017 Q4 5,126,558 $470,559,417 +$234,134,618 $91.79 88
2017 Q3 2,673,071 $120,236,161 +$28,988,629 $44.98 50
2017 Q2 2,046,899 $33,282,527 +$8,857,871 $16.26 39
2017 Q1 1,529,190 $23,547,216 +$3,024,176 $15.40 25
2016 Q4 1,345,552 $20,048,209 +$6,295,667 $14.90 24
2016 Q3 1,006,962 $12,766,000 +$12,739,000 $12.67 24
2016 Q2 79,573 $21,000 +$21,000 $0.26 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .